Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by New York University School of Medicine
Sponsor:
Collaborators:
Synta Pharmaceuticals Corp.
Memorial Sloan-Kettering Cancer Center
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT02060253
First received: January 30, 2014
Last updated: June 4, 2014
Last verified: June 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2016
  Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)